Three Top-Performing Dividend Boosting Stocks to Invest in December for a Long-Term Hold of Over a Decade
In the past couple of years, the stock market has been on a roll, with the S&P 500 index soaring an impressive 57.1% since the end of 2022. However, this bull run has seen stock prices outpace earnings, leaving many income-seeking investors hunting for high-yield dividend stocks. Thankfully, there are still a few gems out there.
First up is Brookfield Infrastructure (BIPC), offering a juicy 3.6% yield. This dividend payer is a no-brainer for anyone who appreciates the reliability of infrastructure. Whether it's energy, data, water, or freight, infrastructure is essential for any economy, so you can be confident that its dividend payout will continue to grow. There are two ways to invest in this high-yield stock: BIPC shares or BIP, a master limited partnership offering a more substantial 4.6% yield.
Investors might be familiar with AbbVie (ABBV), a pharmaceutical powerhouse that doesn't shy away from dividends. Its impressive 3.6% yield might not seem jaw-dropping, but AbbVie has a knack for cranking up its payouts. Since its 2013 split from Abbott Laboratories, AbbVie has more than quadrupled its payout. The company's comparatively low yield is likely due to significant Humira losses, but don't underestimate its potential for future earnings growth – blockbusters like Skyrizi and Rinvoq more than make up for it.
Lastly, we have Royalty Pharma (RPRX), a specialty financier that's been lending to drugmakers for a royalty stake in their products. With a 3.6% yield, Royalty Pharma stands out as an alternative for anyone looking to cash in on the prescription drug trend. Assets like Trikafta — part of Vertex Pharmaceuticals' cystic fibrosis franchise — and its other 15 blockbuster drugs likely make it an excellent choice for investors eager to yield passive income by retirement.
In the realm of finance and investing, many income-seeking individuals are looking for ways to secure reliable dividends. Brookfield Infrastructure (BIPC) and its 3.6% yield, for instance, is a reliable choice due to its essential role in infrastructure sectors such as energy, data, water, and freight. On the other hand, AbbVie (ABBV) with its 3.6% yield, despite facing Humira losses, has a strong track record of dividend growth since its 2013 split, showcasing its potential for future earnings growth.
